Assignment of Neisseria meningitidis serogroups A, C, W135, and Y anticapsular total immunoglobulin G (IgG), IgG1, and IgG2 concentrations to reference sera
- PMID: 14715537
- PMCID: PMC321340
- DOI: 10.1128/cdli.11.1.1-5.2004
Assignment of Neisseria meningitidis serogroups A, C, W135, and Y anticapsular total immunoglobulin G (IgG), IgG1, and IgG2 concentrations to reference sera
Abstract
Meningococcal serogroup-specific immunoglobulin G (IgG), IgG1, and IgG2 concentrations were assigned to three reference sera, CDC 1992, 89-SF, and 96/562, for meningococcal serogroups A, C, Y, and W135 via the method of cross standardization. The sum of the serogroup-specific IgG1 and IgG2 concentrations determined for the four meningococcal serogroups showed good agreement with the serogroup-specific IgG either determined here or as previously represented. Following the assignment of meningococcal serogroup-specific IgG1 and IgG2 concentration to these reference sera, a meningococcal serogroup-specific IgG1 and IgG2 enzyme-linked immunosorbent assay protocol was developed. The serogroup A and C specific subclass distribution of a panel of adult sera collected following vaccination with any combination of meningococcal serogroup C conjugate, bivalent, or tetravalent polysaccharide vaccines was determined. For the determination of serogroup W135 and Y specific subclass distribution, an adolescent panel 28 days following a single dose of either tetravalent polysaccharide or conjugate vaccine was used. The sum of the serogroup-specific IgG1 and IgG2 showed strong correlation with the serogroup-specific total IgG determined. The assignment here of IgG1 and IgG2 subclasses to these reference sera will allow more detailed evaluation of meningococcal conjugate and polysaccharide vaccines.
Figures
Similar articles
-
Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005.Vaccine. 2007 Oct 10;25(41):7233-7. doi: 10.1016/j.vaccine.2007.07.019. Epub 2007 Aug 1. Vaccine. 2007. PMID: 17707957
-
Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135.Clin Diagn Lab Immunol. 2004 Mar;11(2):272-9. doi: 10.1128/cdli.11.2.272-279.2004. Clin Diagn Lab Immunol. 2004. PMID: 15013975 Free PMC article.
-
Immunoglobulin G subclass response to a meningococcal quadrivalent polysaccharide-diphtheria toxoid conjugate vaccine.Clin Vaccine Immunol. 2006 Apr;13(4):507-10. doi: 10.1128/CVI.13.4.507-510.2006. Clin Vaccine Immunol. 2006. PMID: 16603620 Free PMC article.
-
Meningococcal quadrivalent (serogroups A, C, W135, and Y) conjugate vaccine (Menveo(®)): profile report.Paediatr Drugs. 2012 Feb 1;14(1):63-5. doi: 10.2165/11206930-000000000-00000. Paediatr Drugs. 2012. PMID: 22149552 Review. No abstract available.
-
Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.Expert Rev Vaccines. 2009 May;8(5):529-42. doi: 10.1586/erv.09.18. Expert Rev Vaccines. 2009. PMID: 19397410 Review.
Cited by
-
Alternative Complement Pathway Inhibition Does Not Abrogate Meningococcal Killing by Serum of Vaccinated Individuals.Front Immunol. 2021 Oct 8;12:747594. doi: 10.3389/fimmu.2021.747594. eCollection 2021. Front Immunol. 2021. PMID: 34691058 Free PMC article.
-
Kinetics of maternally-derived serogroup A, C, Y and W-specific meningococcal immunoglobulin G in Malian women and infants.Vaccine. 2019 Apr 24;37(18):2477-2481. doi: 10.1016/j.vaccine.2019.03.045. Epub 2019 Apr 2. Vaccine. 2019. PMID: 30952500 Free PMC article. Clinical Trial.
-
Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12-23 Months Following Meningococcal Vaccination.Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S563-9. doi: 10.1093/cid/civ505. Clin Infect Dis. 2015. PMID: 26553689 Free PMC article. Clinical Trial.
-
Impaired antibody response to conjugated meningococcal serogroup C vaccine in asplenic patients.Eur J Clin Microbiol Infect Dis. 2011 May;30(5):611-8. doi: 10.1007/s10096-010-1129-2. Epub 2010 Dec 24. Eur J Clin Microbiol Infect Dis. 2011. PMID: 21184126
-
Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda.PLoS Negl Trop Dis. 2008;2(12):e342. doi: 10.1371/journal.pntd.0000342. Epub 2008 Dec 2. PLoS Negl Trop Dis. 2008. PMID: 19048025 Free PMC article. Clinical Trial.
References
-
- Ambrosino, D. M., M. Wang, A. Ciamarra, M. Chan, D. L. Bolon, J. Minn, D. A. Jacobsohn, and R. W. Finberg. 1994. T cells and natural killer cells regulate human IgG subclass concentrations in SCID mice. Cell. Immunol 155:134-143. - PubMed
-
- Balmer, P., R. Borrow, and E. Miller. 2002. Impact of meningococcal C conjugate vaccine in the United Kingdom. J. Med. Microbiol. 51:717-722. - PubMed
-
- Cambell, J. D., R. Edelman, J. C. King, Jr., T. Papa, R. Ryall, and M. B. Rennels. 2002. Safety, reactogenicity, of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults. J Infect. Dis. 186:1848-1851. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
